title: Skin problems and EGFR-tyrosine kinase inhibitor.
abstract: Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon, pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase inhibitor was first approved for the treatment of advanced lung cancer in 2002. Epidermal growth factor receptor-tyrosine kinase inhibitor plays an essential role in the treatment of cancer, especially for patients harbouring epidermal growth factor receptor activating mutation. Hence, skin toxicity is the most concerning issue for the epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Skin toxicity is bothersome and sometimes affects the quality of life and treatment compliance. Thus, it is important for physicians to understand the background and how to manage epidermal growth factor receptor-tyrosine kinase inhibitor-associated skin toxicity. Here, the author reviewed the mechanism and upfront preventive and reactive treatments for epidermal growth factor receptor inhibitor-associated skin toxicities.
authors.affiliation: Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan tokozuki@shikoku-cc.go.jp.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kozuki
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D010304:Paronychia / Q000139:chemically induced / Q000517:prevention & control; D010353:Patient Education as Topic; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000008:administration & dosage; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D012871:Skin Diseases / Q000139:chemically induced; D013473:Sunscreening Agents / Q000008:administration & dosage; D014812:Vitamin K / Q000008:administration & dosage
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D047428:Protein Kinase Inhibitors; D012176:Retinoids; D013473:Sunscreening Agents; D014812:Vitamin K; C512478:EGFR protein, human; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D001241:Aspirin
keywords: EGFR-TKI; minocycline; rash acneiform; skin rash
references.citation: J Am Acad Dermatol. 2006 Feb;54(2):258-65
references.pmid: 16443056
references.citation: Am J Pathol. 2003 Jul;163(1):303-12
references.pmid: 12819035
references.citation: J Invest Dermatol. 2003 Jun;120(6):1038-44
references.pmid: 12787132
references.citation: Eur J Dermatol. 2010 Jan-Feb;20(1):82-4
references.pmid: 19797039
references.citation: BJU Int. 2011 Nov;108(10):1556-63
references.pmid: 21952069
references.citation: Clin Cancer Res. 2003 Jul;9(7):2478-86
references.pmid: 12855621
references.citation: Anticancer Drugs. 2006 Apr;17(4):423-7
references.pmid: 16550000
references.citation: J Clin Oncol. 2016 Mar 10;34(8):810-5
references.pmid: 26573073
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: Case Rep Dermatol. 2011 May;3(2):130-6
references.pmid: 21743808
references.citation: J Drugs Dermatol. 2005 Jan-Feb;4(1):41-7
references.pmid: 15696984
references.citation: Nat Rev Cancer. 2006 Oct;6(10):803-12
references.pmid: 16990857
references.citation: Acta Derm Venereol. 2008;88(1):84-6
references.pmid: 18176767
references.citation: Mol Cancer Ther. 2005 Apr;4(4):650-8
references.pmid: 15827339
references.citation: Clin Cancer Res. 2010 Jan 1;16(1):304-10
references.pmid: 20028750
references.citation: J Antimicrob Chemother. 1991 May;27(5):607-17
references.pmid: 1885419
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1119-27
references.pmid: 18309947
references.citation: J Invest Dermatol. 2006 Apr;126(4):732-9
references.pmid: 16470170
references.citation: PLoS One. 2013;8(1):e55128
references.pmid: 23383079
references.citation: Clin Cancer Res. 2011 Nov 1;17(21):6766-77
references.pmid: 21914790
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: Pharmacogenomics. 2012 Oct;13(13):1469-76
references.pmid: 23057547
references.citation: Oncologist. 2010;15(9):1016-22
references.pmid: 20798191
references.citation: EMBO J. 1999 Sep 1;18(17):4657-68
references.pmid: 10469645
references.citation: Expert Rev Anticancer Ther. 2013 Jun;13(6):745-58
references.pmid: 23773106
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: Nat Rev Genet. 2002 Mar;3(3):199-209
references.pmid: 11972157
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references.pmid: 12409327
references.citation: J Invest Dermatol. 2001 Jun;116(6):860-6
references.pmid: 11407972
references.citation: J Clin Oncol. 2013 Sep 20;31(27):3327-34
references.pmid: 23816960
references.citation: Science. 1995 Jul 14;269(5221):230-4
references.pmid: 7618084
references.citation: Anticancer Res. 2013 Nov;33(11):4995-8
references.pmid: 24222141
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Br J Dermatol. 2001 Jun;144(6):1169-76
references.pmid: 11422037
references.citation: Semin Radiat Oncol. 2016 Jan;26(1):59-70
references.pmid: 26617211
references.citation: J Cell Sci. 1997 Jan;110 ( Pt 2):113-21
references.pmid: 9044042
references.citation: J Dtsch Dermatol Ges. 2011 Mar;9(3):195-203
references.pmid: 21059173
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: Cancer. 2008 Aug 15;113(4):847-53
references.pmid: 18543329
references.citation: J Clin Oncol. 2002 Jan 1;20(1):110-24
references.pmid: 11773160
references.citation: Pharmacogenomics J. 2008 Apr;8(2):129-38
references.pmid: 17375033
references.citation: J Clin Oncol. 2016 Sep 20;34(27):3248-57
references.pmid: 27022112
references.citation: J Am Acad Dermatol. 2007 Mar;56(3):500-5
references.pmid: 17166623
references.citation: Support Care Cancer. 2011 Aug;19(8):1079-95
references.pmid: 21630130
references.citation: J Thorac Oncol. 2010 Oct;5(10):1662-3
references.pmid: 20871265
references.citation: Clin Exp Immunol. 1979 Mar;35(3):443-6
references.pmid: 455782
references.citation: J Lab Clin Med. 1977 Aug;90(2):259-65
references.pmid: 886211
references.citation: Lancet Oncol. 2014 Feb;15(2):213-22
references.pmid: 24439929
references.citation: Ann Oncol. 2011 Mar;22(3):524-535
references.pmid: 20709812
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Invest Dermatol. 1978 Jan;70(1):51-5
references.pmid: 618981
references.citation: Lancet Oncol. 2014 Oct;15(11):1236-44
references.pmid: 25175099
references.citation: Curr Oncol. 2011 Jun;18(3):126-38
references.pmid: 21655159
references.citation: Curr Oncol. 2009 Jan;16(1):16-26
references.pmid: 19229368
references.citation: Lung Cancer. 2015 Apr;88(1):74-9
references.pmid: 25704957
references.citation: J Invest Dermatol. 1997 Dec;109(6):751-6
references.pmid: 9406816
references.citation: Pancreas. 2013 Jul;42(5):760-73
references.pmid: 23774698
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8195-203
references.pmid: 15623594
references.citation: Br J Dermatol. 2005 Oct;153(4):849-51
references.pmid: 16181478
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5390-6
references.pmid: 18048820
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3913-21
references.pmid: 17606725
references.citation: Cancer Sci. 2015 Sep;106(9):1202-11
references.pmid: 26094656
references.citation: Cancer Res. 2004 Dec 15;64(24):8919-23
references.pmid: 15604253
references.citation: J Clin Oncol. 2014 Jun 20;32(18):1902-8
references.pmid: 24841974
references.citation: Oncologist. 2014 Nov;19(11):1156-68
references.pmid: 25326159
references.citation: Drugs. 2015 Aug;75(12):1335-48
references.pmid: 26187773
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Lung Cancer. 2006 Apr;52(1):99-103
references.pmid: 16503086
references.citation: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references.pmid: 15741570
references.citation: Oncologist. 2009 Aug;14(8):840-7
references.pmid: 19679688
references.citation: Immunopharmacology. 1996 Mar;31(2-3):163-9
references.pmid: 8861742
references.citation: Lung Cancer. 2015 Jun;88(3):282-8
references.pmid: 25882778
references.citation: Cancer Res. 2004 Dec 15;64(24):9139-43
references.pmid: 15604284
references.citation: Anticancer Res. 2003 Sep-Oct;23(5A):3639-50
references.pmid: 14666659
references.citation: J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S96-103
references.pmid: 9204085
references.citation: J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S18-24
references.pmid: 9270552
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: Cell Signal. 2008 Oct;20(10):1830-8
references.pmid: 18644433
references.citation: Clin Cancer Res. 2005 Feb 1;11(3):1167-73
references.pmid: 15709185
references.citation: Lung Cancer. 2013 Oct;82(1):109-14
references.pmid: 23910906
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1351-7
references.pmid: 20142600